摘要
目的:利用常规药物加心区交感神经阻滞(CSNB)技术治疗(以下简称治疗)慢性心力衰竭,观察治疗前后患者血浆N-端脑利钠肽前体(NT-pro BNP)水平变化情况及利用NT-pro BNP评价常规药物加CSNB对心衰治疗的有效性。方法:对54例慢性心衰患者给予常规药物加CSNB治疗,比较治疗前后血浆NT-pro BNP的水平、左室射血分数(LVEF)、左室舒张末内径(LVEDD)变化情况,随访6个月内不良事件(以下简称事件)发生率(包括全因病死率和再入院率之和)。结果:治疗后患者3-8分钟即感觉呼吸困难等临床症状体征明显减轻,住院期间患者尿量明显增多,无一例死亡;治疗14日及出院时血浆NT-pro BNP明显下降(出院时下降比例为61.4%),与治疗前比较其差异有显著统计学意义(P<0.01);LVEF升高,与治疗前比较其差异有显著统计学意义(P<0.01);住院14日及出院时LVEDD较入院时缩小。随访6个月,发生事件12例(22.2%)。结论:NT-pro BNP是评价心衰治疗有效性的可信指标,常规药物加CSNB治疗心衰的临床疗效明显优于单纯常规药物治疗。
Objective： To observe of changes plasma N-terminal brain natfiuretic peptide （NT-proBNP）level in patients with chronic heart failure（CHF） undergone cardiacsympathetic blockade（CSNB） treatment with conventional drugs, and evaluate the value of NT-proBNP in predicting CSNB for the treatment of CHF. Methods： A total of 54 cases of CHF patients undergone CSNB with conventional drugs were measured Plasma NT-proBNP level, LVEF and LVEDD, Patients were followed up for 6 months, The primary end point was adverse events incliding all-cause mortality and readmission. Results： The symptoms of dyspnea were reduced at 3-8 minutes after treatment, The urine volume of patients increased significantly, and there was no case of death at hospitalization period, Plasma NT-proBNP decreased significantly （61.4） at 14 days and Discharged （P 〈 0.01）, LVEF increased than 14 days and Discharged （P 〈 0.01） and LVEDD reduced, the event rate following up for 6 months was 22.2. Conclusion： The NT- proBNP level is credible for evaluation of treatment in CHF. The clinical curative effect of CSNB with conventional drugs is better than conventional drugs for the treatment in CHF.
出处
《现代生物医学进展》
CAS
2015年第34期6762-6765,共4页
Progress in Modern Biomedicine
基金
黑龙江省科技厅科学技术研究项目(GC06C41902)
关键词
慢性心力衰竭
N-端脑利钠肽前体
心区交感神经阻滞
Chronic heart failure
N-terminal brain natriuretic peptide
Cardiac sympathetic blockade
